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Models describing the structural changes 
mediating cys-loop receptor activation 
generally give little attention to the possibility 
that different agonists may promote activation 
via distinct M2 pore-lining domain structural 
rearrangements. We investigated this question 
by comparing the effects of different ligands 
on the conformation of the external portion of 
the homomeric α1 glycine receptor M2 
domain. Conformational flexibility was 
assessed by tethering a rhodamine fluorophore 
to cysteines introduced at the 19’ or 22’ 
positions and monitoring fluorescence and 
current changes during channel activation. 
During glycine activation, fluorescence of the 
label attached to R19’C increased by ~20% 
and the emission peak shifted to lower 
wavelengths, consistent with a more 
hydrophobic fluorophore environment. In 
contrast, ivermectin activated the receptors 
without producing a fluorescence change. 
Although taurine and β-alanine were weak 
partial agonists at the α1R19’C GlyR, they 
induced large fluorescence changes. Propofol, 
which drastically enhanced these currents, did 
not induce a glycine-like blue-shift in the 
spectral emission peak. The inhibitors, 
strychnine and picrotoxin, elicited fluorescence 
and current changes as expected for a 
competitive antagonist and an open channel 
blocker, respectively. Glycine and taurine (or 
β-alanine) also produced an increase and a 
decrease, respectively, in the fluorescence of a 
label attached to the nearby L22’C residue. 
Thus, results from two separate labelled 
residues  support the conclusion that the GlyR 
M2 domain responds with distinct 
conformational changes to activation by 
different agonists.  
 
Glycine receptor chloride channels (GlyRs) 
mediate inhibitory neurotransmission in the 
central nervous system (1). They comprise an 
assembly of five subunits that are each composed 
of a large N-terminal extracellular (EC) ligand-
binding domain and 4 transmembrane α-helices 
(M1-M4). Cryo-electron microscopy images of 
the homologous Torpedo electropax nicotinic 
acetylcholine receptor (nAChR) transmembrane 
region reveals that the pore-lining M2 domains 
are kinked radially inwards to form a central 
constriction at the membrane midpoint (2).  There 
is currently a great deal of interest in 
understanding how M2 domains move to open the 
channel. Whereas the original model proposed a 
drastic rotation of M2 domains about their long 
axes (3), more recent evidence suggests that there 
is little if any rotation during receptor activation 
(4-6). The precise nature of the structural change 
remains a matter for debate. 
The central pore kink is likely to 
introduce a degree of structural discontinuity 
because the hydrogen bonds responsible for 
maintaining α helix rigidity are most likely 
broken. The kink may therefore act as a swivel 
enabling the outer half of M2 to move 
asynchronously with the inner half, where the 
gate is most likely positioned. Indeed, several 
lines of evidence suggest gating is mediated by a 
backbone rearrangement at this midpoint (7-10). 
In addition, a rate-equilibrium free-energy state 
analysis shows that the M2-M3 domain is 
positioned midway along the agonist-induced 
‘conformational wave’ that extends from the 
ligand binding domain to the gate (11). These 
considerations imply that the outer part of M2 
should be an informative place to investigate the 
structural basis of receptor activation, as the 
movements in this region should not reflect either 
those occurring at the ligand binding site or the 
activation gate. Thus, in the present study we 
probe conformational changes at the 19’ and 22’ 
residues, near the external end of M2. 
Current models of cys-loop receptor 
activation consider only structural changes 
associated with transitions from the resting closed 
to the agonist-induced open states (5, 6, 12, 13). 
Relatively little attention has been given to the 
possibility that different agonists and 
pharmacological modulators may promote 
different structural conformations in the pore 
region. However, it has been suggested on the 
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basis of substituted cysteine accessibility studies 
that the pore blocker, picrotoxin, can change the 
conformation of the outer GlyR pore region 
suggesting in turn that it may interact 
allosterically with agonist-induced 
conformational changes (14). Our aim is to 
investigate the conformational changes induced 
by agonists, antagonists and allosteric modulators 
by covalently labeling different residues near the 
extracellular M2 boundary with the sulfhydryl-
reactive fluorophores, methanethiosulfonate-
rhodamine (MTSR) and tetramethylrhodamine-
maleimide (TMRM), and simultaneously 
measuring current changes and fluorescence 
changes (15, 16). This approach has been 
employed so far in only a few studies on cys-loop 
receptors (15, 17, 18). A particular advantage of 
the GlyR is that it displays little or no 
desensitization thereby facilitating the 
quantitation of ligand-induced fluorescence 
spectral shifts.   
 
EXPERIMENTAL PROCEDURES 
 
Chemicals - Glycine, CaCl2, MgCl2, KCl, NaCl 
and glycerol were all purchased from Ajax 
Finechem (Seven Hills, NSW). 4-(2-
Hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) was purchased from Amresco (Solon, 
Ohio). Sulforhodamine methanethiosulfonate 
(MTSR, Toronto Research Chemicals, North 
York, ON) and tetramethylrhodamine-5-
maleimide (TMRM, Invitrogen Corp., Carlsbad, 
CA) were dissolved in dimethylsulfoxide 
(DMSO) and stored at -20°C. Picrotoxin (Sigma 
Aldrich), ginkgolide C (Tauto Biotech Co., 
Shanghai, China) and ivermectin (Sigma Aldrich) 
were dissolved in DMSO and stored at -20°C. 
Propofol (2,6-diisopropylphenol) was purchased 
from Sigma Aldrich and stored at 4°C. Strychnine 
(Sigma Aldrich) was dissolved in water and 
stored at -20°C. Taurine (Sigma Aldrich) and β-
alanine (Sigma Aldrich) were also dissolved in 
water and stored at 4°C.  
 
Molecular Biology - The human GlyR α1 subunit 
cDNA was subcloned into the pGEMHE vector. 
All constructs used in this study contained the 
functionally-silent C41A mutation which 
eliminated the sole uncrosslinked extracellular 
sulfhydryl group (19). Site directed mutagenesis 
to generate the R19’C, S21’C and L22’C mutants 
was performed with the QuickChange 
mutagenesis kit (Stratagene, La Jolla, CA). 
Successful incorporation of the mutations was 
confirmed through automated sequencing of the 
entire cDNA coding region. The mMessage 
mMachine Kit (Ambion, Austin, TX) was used to 
generate capped mRNA for oocyte injection. 
mRNA concentrations were adjusted to 200 pg / 
nl and aliquots stored at -70°C 
 
Oocyte Preparation, Injection and Labeling - 
Female Xenopus laevis (Xenopus Express, 
France) frogs were anesthetized and stage VI 
oocytes were removed from ovaries and washed 
thoroughly in OR-2 (2.5 mM NaCl, 2 mM KCl, 1 
mM MgCl2, 5 mM HEPES, pH 7.4). The oocytes 
were incubated in collagenase (Sigma Aldrich, St 
Louis, MO) in OR-2 for 2 hrs at room 
temperature, rinsed and stored at 18°C. 
All oocytes were injected with 10 ng of 
mRNA into the cytosol. To achieve the high 
levels of expression required for the detection of 
the fluorescent signal over the background (due to 
oocyte autofluorescence and non-specific binding 
of the dye) the oocytes were incubated for 3-10 
days after injection at 18°C. The incubation 
solution contained 96 mM NaCl, 2 mM KCl, 1 
mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES, 0.6 
mM Theophylline, 2.5 mM Pyruvic Acid, 50 
µg/ml Gentamycin (Cambrex Corporation, East 
Rutherford, NJ), 5% Horse serum (Hyclone, 
Logan, UT), pH 7.4.  
To maximise surface expression of 
receptors prior to labeling, oocytes were 
incubated at room temperature for 2 hrs. The 
oocytes were then transferred into ND96 (96 mM 
NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 
mM HEPES, pH 7.4) and stored on ice. For 
labeling, oocytes were transferred into the 
labeling solution containing 10 µM MTSR in 
ND96 for 25 sec or 10 µM TMRM in ND96 for 
60 min. The oocytes were then washed and stored 
in ND96 for up to 6 hrs before recording. All 
labeling steps were performed on ice. 
 
Voltage-clamp Fluorometry (VCF) - For VCF 
experiments an inverted Nikon Eclipse TE300 
microscope (Nikon Instruments, Kawasaki, 
Japan) was equipped with a high-Q 
tetramethylrhodamine isothiocyanate filter set 
(Chroma Technology, Rockingham, VT), a Plan 
Fluor 40x objective lens (N.A. 0.6, WD 3.7-2.7 
mm) (Nikon Instruments, Kawasaki, Japan), and 
a PhotoMax 200 photodiode detection system 
(Dagan Corporation, Minneapolis, MN) attached 
to the side port of the microscope. An excitation 
filter wheel including a shutter and an emission 
filter wheel were controlled through a Lambda 
10-2 unit (Sutter Instruments, Novato, CA). A 
Lambda LS 175-Watt xenon arc lamp served as a 
          
   
 3
light source and was coupled to the microscope 
via a liquid light guide (Sutter Instruments, 
Novato, CA). The design of the custom made 
recording chamber is described in (15). An 
automated perfusion system operated by a 
Valvebank 8 module (AutoMate Scientific, San 
Francisco, CA) was used for perfusion of the 
recording chamber. 
Electrodes for two-electrode voltage 
clamp recordings were filled with 3 M CsCl and 
moved by automated ROE-200 
micromanipulators coupled to an MPC-200 
controller (Sutter Instruments, Novarto, CA). 
Cells were voltage-clamped at a holding potential 
of -40 mV in all experiments, and currents were 
recorded using a Gene Clamp 500B amplifier 
(Molecular Devices). Current and fluorescence 
traces were acquired at 200 Hz via a Digidata 
1322A interface and Clampex 9.2 software 
(Molecular Devices). The fluorescence signal was 
further digitally filtered at 1-2 Hz with an eight-
pole Bessel filter for analysis and display. The 
baseline was corrected for bleaching where 
appropriate. All values for changes in 
fluorescence indicate an increase in fluorescence, 
unless stated otherwise. The empirical Hill 
equation, fitted with a non-linear least squares 
algorithm (SigmaPlot 9.0, Systat Software, Point 
Richmond, CA), was used to obtain half-maximal 
concentrations (EC50 or IC50) and Hill coefficient 
(nH) values for ligand-induced activation and 
inhibition. All results are expressed as mean ± 
standard error of the mean of five or more 
independent experiments. 
 
Spectral Analysis - For spectral analysis a 
MicroSpec 2150i (Acton Research Corporation, 
Acton, MA) coupled to an ORCA-ER CCD 
camera (Hamamatsu, Hamamatsu City, Japan) 
replaced the photodiode detection system on the 
side port of the microscope. The spectrometer 
was operated using SpectraPro Monochromator 
Software (Acton Research Corporation, Acton, 
MA). For excitation, a HQ535/50x filter was used 
in combination with a Q565LP dichroic mirror 
(Chroma Technology, Rockingham, VT); no 
emission filter was used. Prior to the experiment, 
the spectrometer was calibrated using the 434, 
546 and 577 nm lines of a mercury lamp 
spectrum. 
To analyse spectra, the image of the 
region of interest to be monitored was aligned 
with the slit of the spectrometer. Fluorescence 
from the region of interest was reflected onto the 
grating (300 g / mm; 500 nm blaze) and the 
extracted spectrum was imaged on the ORCA-ER 
CCD (chip size 1344 x 1024 pixels) using 
MetaMorph 6.2 (Universal Imaging Corporation, 
Downington, PA). The x axis of the resulting 
“spectral image” represents the wavelength 
dimension while the y axis represents the 1D 
spatial dimension of the slit. The wavelength 
coverage for this combination of grating and 
camera was 170 nm. Adjacent averaging (15 
points) was used to smooth recorded spectra 
(ORIGIN 6.0, Microcal Software Inc., 
Northampton, MA) 
 
RESULTS 
 
Specific MTSR-labeling of the α1R19’C GlyR  
Fig. 1A shows examples of glycine-
evoked currents recorded from oocytes injected 
with α1WT RNA (upper panel) or mutant 
α1R19’C RNA (lower panel). The averaged 
glycine dose-response curves are shown in Fig. 
1C. In this and all subsequent figures displaying 
dose-response curves, the continuous lines 
represent fits of the Hill equation to the averaged 
points. Table 1 shows the mean EC50 and nH 
values, determined by averaging the parameters 
determined from curve fits to individual dose-
responses. This table also shows the mean Imax 
values. As previously reported (20), the α1R19’C 
mutation results in a dramatically decreased 
glycine sensitivity. The mean Imax was not 
significantly different in α1R19’C relative to 
α1WT receptors (9.3 ± 1.6 µA, n = 5, versus 10.0 
± 0.6 µA, n = 9). The effect of MTSR labeling on 
glycine-evoked currents was also studied. As 
shown in the example in Fig. 1B (upper panel), 
our standard MTSR labeling protocol produced 
no significant change (+11.7 ± 8.1 %, n = 8) in 
the magnitude of currents activated by EC10 (5 
µM) glycine in α1WT GlyRs (Fig. 1B, upper 
panel). However, EC10 (1 mM) glycine currents 
were strongly potentiated in α1R19’C GlyRs 
following MTSR-labeling with a mean current 
increase of 471 ± 68 % (n = 6) (e.g., Fig. 1B, 
lower panel). As shown in Fig. 1C, this was 
caused by a leftward shift in the α1R19’C GlyR 
glycine EC50 value, although the nH remained 
unchanged (Table 1). As expected, the mean 
glycine EC50 of the α1WT GlyR was not 
significantly changed by the MTSR labeling 
procedure (Fig. 1C, Table 1). 
Fig. 1D shows a model of three nAChR 
M2 helices (based on PDB code 2BG9), one of 
which shows the approximate relative locations 
of the labeled rhodamine (Lester, HA & Dibas 
MI, manuscript in preparation) and the 9’ leucine 
residue thought to be part of the channel gate. 
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Glycine-evoked Changes in Fluorescence 
Intensity at R19’C 
MTSR treatment of oocytes injected with 
α1R19’C mRNA resulted in a ~3.5 fold increase 
in resting fluorescence compared to that observed 
in identically treated uninjected oocytes or 
oocytes injected with α1WT mRNA (data not 
shown). Voltage-clamp fluorometry (VCF) 
experiments showed that glycine application 
produced changes in fluorescence intensity (∆F) 
in α1R19’C injected oocytes that were coincident 
in time with the activated chloride current (∆I) 
(Fig. 2A), with relative changes in fluorescence 
(∆F/F) regularly reaching 20% at saturating 
glycine concentrations.  In contrast, no significant 
∆F was ever observed with uninjected or α1WT -
injected oocytes. When normalized, the ∆I and 
∆F glycine dose-response were virtually 
superimposed (Fig. 2B, Table 1), strongly 
suggesting a tight coupling between 
conformational changes at the 19’ residue and at 
the channel gate during glycine-induced 
activation. 
Spectral analysis of the fluorescence 
signal from MTSR-labeled α1R19’C GlyRs 
revealed that the fluorescence increase was 
accompanied by a ~10 nm blue-shift (n = 6) in the 
MTSR emission peak during full receptor 
activation (Fig. 2C, D). The magnitude of this 
shift was concentration-dependent. with EC50 (1 
mM) glycine producing roughly half of the shift 
produced by a saturating (20 mM) glycine 
concentration (Fig. 2C, D). The blue-shift in the 
MTSR emission peak is characteristic of an 
increase in hydrophobicity in the fluorophore 
environment, most likely reflecting a movement 
of the fluorophore to a more hydrophobic 
environment in the open state (15). As expected, 
MTSR-incubated oocytes expressing α1WT 
GlyRs did not show ∆F or spectral shifts (Fig. 
2D). 
 
Effects of other agonists on R19’C fluorescence 
changes 
The anti-helminthic compound, 
ivermectin, binds to an as yet unidentified 
binding site and activates the GlyR in an 
irreversible manner (21). To confirm the previous 
conclusion that it activates the GlyR via a 
different mechanism from glycine (21), we 
sought to compare the relationship between ∆I 
and ∆F produced by ivermectin with that 
produced by glycine. In MTSR-labeled α1R19’C 
GlyRs, 10 µM ivermectin evoked slowly 
developing currents that were roughly double the 
size of those produced by 1 mM glycine (203 ± 
30%, n = 10). Despite this large current, no 
significant increase in the fluorescence intensity 
was ever observed (e.g., Fig. 3A). Indeed, the 
mean fluorescence change in 8 oocytes showing 
robust glycine currents, the ∆F response was only  
0.5 ± 0.1 %. As previously observed (21), the 
currents evoked by 10 µM ivermectin were only 
weakly sensitive to strychnine, with 10 µM 
strychnine reducing current magnitude by 18.9 ± 
0.7 % ( n = 4, Fig 3B). No ivermectin-gated 
currents were observed in uninjected oocytes (n = 
3). Taken together, these results confirm that 
ivermectin activates GlyRs by a mechanism 
different from glycine. 
Taurine and β-alanine are low efficacy 
agonists of α1WT GlyRs, with taurine having a 
lower efficacy than β-alanine (22). Both 
compounds are converted into antagonists by a 
variety of R19’ mutations including R19’C (20, 
23, 24). These actions suggest that taurine and β-
alanine bind to the α1R19’C GlyR without 
activating the receptor and thereby they act as 
classical competitive antagonists of glycine 
binding. If this hypothesis is correct, their binding 
should not produce significant ∆F. We sought to 
investigate whether these ligands produced a 
significant ∆F change upon receptor binding, and 
if so, whether this was spectrally similar to that 
produced by glycine. As expected, a 50 mM 
concentration of taurine did not produce a 
significant ∆I, although small, nA sized currents 
were regularly recorded. Nevertheless, 50 mM 
taurine produced large changes in ∆F, with a 
mean value near 35 % of that evoked by a 
saturating glycine concentration (Fig. 3C). Both 
∆I and ∆F stimulated by taurine were completely 
blocked by 10 µM strychnine (data not shown). 
Similar results were obtained with β-alanine. A 
50 mM concentration of β-alanine evoked only a 
very small current (~4% of that produced by 
saturating glycine in the same oocyte), but it 
evoked a large ∆F that was roughly 60% of that 
produced by a saturating glycine concentration 
(Fig. 3D). Again, both ∆I and ∆F stimulated by 
β-alanine were potently blocked by 10 µM 
strychnine (data not shown). 
The taurine-activated current was too 
small to be fitted with confidence to the Hill 
equation (n = 8). However, Hill equation fits to 
taurine ∆F dose-responses (Fig. 3E) from the 
same 8 oocytes yielded a mean EC50 of 2.4 ± 0.4 
mM and nH of 0.9 ± 0.1. Applications of 
increasing β-alanine concentrations revealed a 
close relationship between ∆F and ∆I with no 
significant differences in their EC50 and nH values 
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(Fig. 3E). The ∆F dose-response was fitted with a 
mean EC50 of 2.02 ± 0.34 mM and an nH of 0.8 ± 
0.1 while the ∆I dose-response was fitted with an 
EC50 of 2.61 ± 0.93 mM and an nH of 1.1 ± 0.4 (n 
= 6 for each). To facilitate comparison with 
glycine-mediated responses, Fig. 3E also shows 
the ∆I and ∆F dose-response relationships for 
glycine activation. The fluorescence and current 
maxima for taurine and β-alanine were both 
normalized to those produced by glycine in the 
same oocyte.  
Given that the relationship between ∆I and ∆F 
produced by glycine activation was not preserved 
during receptor activation by taurine or β-alanine, 
we hypothesized that these compounds produced 
different conformational changes at the 19’ 
residue. We investigated this by measuring the 
spectral changes produced by both compounds. 
As shown in Fig. 3F, taurine binding produced no 
detectable spectral shift, whereas the spectral shift 
produced by β-alanine (~5 nm) was much smaller 
than that produced by glycine (Fig. 3G). Together 
these results strongly suggest that the binding of 
these weak partial agonists results in different 
conformational changes from those produced by 
glycine.  
 
Fluorescence responses of other labeled residues 
in the extracellular M2 region 
As the R19’C mutation impacts severely 
on receptor function, we assessed whether other 
cysteine mutants in the extracellular M2 region 
with less impact on receptor function show a 
similar pattern of differential responses to 
different agonists. A previous study (20) showed 
that cysteine substitutions at the 21’ and 22’ 
positions disrupt receptor function to a lesser 
degree than the R19’C mutation. Thus, we 
focussed on these two residues. When injected 
into oocytes, the α1S21’C GlyR exhibited a WT-
like glycine EC50 although the nH was 
significantly reduced (Table 1). The α1S21’C-
injected oocytes showed no evidence of labeling 
by either MTSR or TMRM. Incubation with 
MTSR or TMRM in the presence or absence of 
100 µM glycine produced no significant ∆F in 
response to saturating (3 mM) glycine 
applications (n = 3 each, data not shown) and 
fluorophore labeling produced no change in 
α1S21’C GlyR electrophysiological properties 
(Table 1). We conclude that α1S21’C is either not 
labeled by these fluorophores or that it 
experiences no change in microenvironment 
during receptor activation.  
The α1L22’C GlyR showed robust 
expression with electrophysiological properties 
intermediate between those of α1WT and 
α1R19’C (Table 1). Importantly, taurine and β-
alanine acted as strong partial agonists (see 
below), as at α1WT receptors. When receptors 
were labeled with MTSR, no change in ∆F could 
be detected, even at saturating (3 mM) glycine 
concentrations (n = 4) (Fig. 4A). However, 
following labeling by TMRM, α1L22’C-injected 
oocytes showed a small but significant ∆F (1.5 ± 
0.3 %, n = 13) at saturating glycine 
concentrations (Fig. 4A). TMRM labeling also 
produced a significant increase in the glycine 
sensitivity of α1L22’C GlyRs (Table 1 and Fig. 
4B). The small size of these signals precluded 
quantitation or spectral analysis of the ∆F 
response. In contrast to the effect of glycine, 
application of saturating (10 mM) concentrations 
of taurine or β-alanine evoked a significant 
decrease in ∆F (Fig. 4C/D). Taurine induced a 
maximal current of 1.7 ± 0.4 µA and a ∆F of -1.1 
± 0.2 % (n = 8). β-Alanine induced a maximal 
current of 3.1 ± 0.3 µA and a ∆F of -1.1 ± 0.3 % 
(n = 7). We then tested whether the sign of the 
fluorescence change simply depended on the size 
of the current or was indeed agonist-specific. 
Application of a low (100 µM) glycine 
concentration evoked currents of 1.6 ± 0.3 µA (n 
= 7), a value not significantly different from those 
evoked by 10 mM taurine (1.7 ± 0.4 µA). 
However, this concentration of glycine produced 
no significant ∆F (0.0 ± 0.1 % compared to -1.1 ± 
0.2 %) (n=7). A similar result was obtained for β-
alanine, where currents induced by 300 µM 
glycine were not significantly different from 
those evoked by 10 mM β-alanine (3.8 ± 0.6 µA 
and 3.1 ± 0.3 µA, respectively) but the respective 
fluorescence changes were significantly different 
in size and sign (0.3 ± 0.2 % compared with -1.1 
± 0.3 %; both n = 7). Together these results 
demonstrate that glycine produces a different 
conformational change at L22’C relative to those 
produced by taurine and β-alanine.  
 
Effects of GlyR inhibitors on R19’C fluorescence 
changes  
We next sought to compare the effects on 
the relationship between ∆I and ∆F of a putative 
classical competitive antagonist, strychnine, an 
allosteric inhibitor, picrotoxin, and a putative 
classical channel blocker, ginkgolide C. The 
molecular pharmacology of each of these 
compounds at the GlyR has recently been 
reviewed (25). When applied alone, strychnine 
did not evoke significant ∆I or ∆F changes, even 
at a concentration of 10 µM (Fig. 5A). However, 
when co-applied with 1 mM glycine, 10 µM 
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strychnine simultaneously decreased ∆I and ∆F 
(Fig. 5B). As shown in Fig. 5C, the sensitivities 
of ∆I and ∆F to strychnine were very similar. 
Analysis of the strychnine ∆I dose-response 
relationships yielded IC50 and nH values of 114.2 
± 9.4 nM and 1.4 ± 0.1 (n = 5) whereas the ∆F 
dose-responses were fitted by IC50 and nH values 
of 142.5 ± 14.4 nM and 1.3 ± 0.2 (n = 5). Thus, 
strychnine itself cannot induce conformational 
changes that are detectable with a fluorophore 
attached to α1R19’C, although it can antagonize 
glycine-induced conformational changes. This 
response profile is expected for a classical 
competitive antagonist. 
On the basis of a substituted cysteine 
accessibility analysis, it was recently proposed 
that picrotoxin can induce a conformational 
change in the M2-M3 loop that is not produced 
by glycine (14). We thus hypothesized that 
picrotoxin may produce a different relationship 
between ∆I and ∆F than was produced by glycine. 
Application of picrotoxin alone did not produce 
any changes in ∆I or ∆F, even at a concentration 
of 50 µM (Fig. 5D). Although co-application of 
50 µM picrotoxin with 1 mM glycine potently 
blocked the current, the ∆F remained intact (Fig. 
5E). Dose-response analysis of ∆I yielded an IC50 
of 626.1 ± 11.4 nM and an nH of 1.0 ± 0.2 (both n 
= 6). However, in the same six oocytes, ∆F 
showed full amplitude over a broad range of 
picrotoxin concentrations (Fig. 5F). This response 
profile is expected for a classical open-state 
blocker that plugs the pore without altering the 
normal open-state conformation. Although it 
provides no evidence to support the previous 
conclusion for picrotoxin imposing a distinct 
conformational change in the M2-M3 loop (14), 
we cannot eliminate the possibility that such a 
conformational change may occur without a 
change in hydrophobicity at R19’C. 
We next investigated the effects of the 
GlyR pore blocker, ginkgolide C. As with 
strychnine and picrotoxin, high concentrations 
(100 µM) of ginkgolide C applied alone did not 
evoke detectable ∆I or ∆F (Fig. 5G). When co-
applied with 1 mM glycine, ginkgolide C 
decreased ∆I but dramatically increased ∆F (Fig. 
5H). Dose-responses averaged from six oocytes 
revealed an averaged ∆I IC50 of 4.6 ± 2.4 µM and 
an nH of 0.5 ± 0.1 and an averaged ∆F EC50 of 
19.6 ± 4.1 µM and an nH of 1.0 ± 0.1 (Fig. 5I). 
Spectral analysis revealed that the effect of 
ginkgolide C on the MTSR emission spectrum 
was similar to that produced by saturating glycine 
concentrations (compare Fig. 5K with Fig. 2D, 
inset). An exception is the ginkgolide C-induced 
hump near 625 nm for which we have no 
explanation. Overall, the results indicate that pore 
block by ginkgolide C induces a conformational 
change in M2-M3 similar to that produced by 
saturating concentrations of glycine.  
 
Analysis of the effects of the GlyR potentiating 
agent, propofol 
Propofol is an intravenous anaesthetic 
that potentiates GlyRs by binding to the alcohol 
and anaesthetic binding site located between TM2 
and TM3 (26, 27). Its potentiation, particularly of 
taurine- and β-alanine-gated currents, is 
facilitated by mutations to R19’ in α1 GlyRs 
(28). As propofol is hydrophobic and its putative 
binding site lies in close proximity to the 19’ 
labeled MTSR, it may directly affect fluorescence 
by modulating the hydrophobicity of the 
environment surrounding the fluorophore. 
However, there was no significant change in the 
basal fluorescence level when MTSR-labeled 
α1R19’C GlyRs were incubated with 500 µM 
propofol for 2 min. Similarly, pre-incubation with 
propofol and subsequent MTSR-labeling in the 
presence of propofol (500 µM each) did not 
change ∆Fmax or the resting fluorescence intensity 
(data not shown). Following a 2 min incubation 
with 500 µM propofol, MTSR-labeled α1R19’C 
GlyRs retained the ability to produce robust 
current and fluorescence changes in response to 
increasing glycine concentrations (Fig. 6A). 
Propofol pre-treatment significantly increased the 
∆Imax but not ∆Fmax value and significantly 
reduced the mean glycine EC50 values for both ∆I 
and ∆F (Fig. 6B, Table 2).  
The same propofol pre-treatment 
drastically increased the taurine- and β-alanine-
mediated ∆I responses although their ∆F values 
were less affected (Fig. 6C, D). The effects of 
propofol on averaged ∆I and ∆F dose-responses 
for taurine and β-alanine are summarized in Fig. 
6E and F, respectively, with mean parameters of 
best fit to the dose-response curves summarized 
in Table 2. As with glycine-mediated responses, 
the taurine- and β-alanine-mediated ∆F EC50 
values were shifted to significantly lower values. 
The ∆Fmax value for taurine was significantly 
increased by propofol, whereas the corresponding 
value for β-alanine was not. The ∆Imax values for 
both taurine and β-alanine were also significantly 
increased by propofol. Considering that propofol 
converted β-alanine and taurine into highly 
efficacious agonists, we tested whether their ∆F 
characteristics may have changed to more closely 
resemble those produced by glycine. Surprisingly, 
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however, propofol had no effect on the spectral 
maxima of the ∆F increases induced by either β-
alanine or taurine (Fig. 6G, H). 
 
DISCUSSION 
 
Structural basis for fluorescence change 
Given the distance of R19’C and L22’C 
from the glycine binding site (12) and their 
position midway along the conformational wave 
that extends from the binding site to the 
activation gate upon agonist binding (11), we 
propose that fluorescence signals arising from 
rhodamine-labeled R19’C and L22’C are not 
likely to simply reflect ligand binding. They are 
more likely to result from a rotation or tilting of 
the M2 helix during the conformational change 
that ultimately leads to channel opening. During 
this global conformational rearrangement, the 
MTSR fluorophore at the 19’ position may move 
to a more hydrophobic environment. TMRM 
attached to L22’C moves into a more 
hydrophobic environment when activated by 
glycine, but moves into a more hydrophilic 
environment when activated by taurine or β-
alanine. However, we can not rule out the 
possibility that a quenching group moving 
towards or away from the fluorophores may 
contribute to the observed fluorescence changes. 
Our experiments do not allow us to discriminate 
among the existing structural models of cys-loop 
receptor activation although they do permit us to 
compare M2 domain conformational changes 
produced by different ligands. 
 
Agonist-induced conformational changes 
Perhaps our most dramatic result is that 
ivermectin activates the pore without producing a 
significant ∆F in the 19’-attached MTSR. 
Although it has previously been suggested that 
ivermectin and glycine activate the GlyR pore via 
structurally different mechanisms (21), the 
present result provides a much stronger case for 
this conclusion. The cys-loop receptor ivermectin 
binding site is yet to be identified. Being 
lipophilic, it is possible that ivermectin binds 
either to a transmembrane or an intracellular site. 
Regardless of where it binds or how it activates 
the receptor, it is surprising that ivermectin opens 
the pore with no detectable change in the 
conformation at the top of M2. This raises the 
intriguing possibility that ivermectin produces 
conformational changes at the internal part of the 
M2 domain only, perhaps via an interaction with 
the M1-M2 linker. 
Taurine and β-alanine are low efficacy 
glycinergic agonists that are converted into 
antagonists by R19’ mutations (20, 23, 24). 
Although their efficacy at activating GlyR 
currents was very weak, both ligands evoked  
large ∆F responses that were not accompanied by 
blue shifts in the spectral emission peak (Fig. 3F, 
G). This response profile differs drastically from 
that produced by glycine, which was 
characterized by a close coupling between ∆I and 
∆F and a substantial blue-shift in the emission 
spectral peak. Thus, the conformational change at 
R19’ produced by these ligands is distinct from 
that produced by glycine. This is not surprising 
because it was already evident from their low 
efficacy that taurine and β-alanine must produce 
different conformational changes to glycine.  
However, propofol, which drastically increased 
the efficacy with which taurine- and β-alanine 
were able to activate ∆I, had no effect on the 
spectral properties of the concomitant ∆F (Fig. 
6G, H). This result is more significant as it shows 
that taurine and β-alanine produce no ∆F spectral 
change even when they strongly activate the 
GlyR. This provides a stronger case for taurine 
and β-alanine activating the GlyR pore via a 
different conformational change to glycine. 
However, a weakness in this argument is that the 
R19’C mutation may have altered structure and 
function to the extent that the results may not 
apply to the WT GlyR. 
For this reason, we compared the agonist-
specific conformational changes experienced by a 
TMRM attached to the nearby L22’C residue. 
Again, we found that glycine produced a different 
∆F response to that elicited by taurine and β-
alanine (Fig. 4C, D). This shows that the agonist-
specific conformational changes do not pertain 
only the functionally-impaired α1R19’C GlyRs 
but also to a nearby mutant with functional 
characteristics that more closely resemble the 
αWT GlyR. 
Together, these results lead us to 
conclude that different agonists activate the GlyR 
by producing different conformational changes to 
the external region of the M2 domain. Thus, the 
top of M2 seems to display a conformational 
mobility which is not necessarily coupled to 
movements of the channel gate. Conversely, 
opening of the channel gate does not necessarily 
propagate back to the top of M2. 
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Antagonists 
Strychnine has long been considered a 
classical competitive antagonist of the GlyR (1). 
Our finding that strychnine exhibits very similar 
inhibitory dose-responses profiles for ∆I and ∆F 
is consistent with this notion. By displacing 
glycine from its site, strychnine prevents glycine 
from binding and hence from inducing its ∆F 
change.  
Picrotoxin is thought to bind in the GlyR 
pore and to produce inhibition via an allosteric 
mechanism (25). We recently concluded on the 
basis of a substituted cystine accessibility study 
that it changes the M2-M3 loop conformation in a 
manner that cannot be achieved by glycine (14). 
If so, then picrotoxin might be expected to alter 
∆F in a way that cannot be achieved by altering 
glycine concentration alone. However, we found 
that ∆F produced by picrotoxin plus glycine 
equals that produced by glycine alone (Fig. 5D-
F). This response profile is expected for a 
classical pore blocker that blocks current flow 
without altering the open state receptor 
conformation. However, we cannot rule out the 
possibility that picrotoxin changes the 
conformation of the M2-M3 loop in a way that 
does not involve a ∆F change. 
Several lines of evidence suggest that 
ginkgolides bind in the GlyR pore (29-31) but 
there is no evidence to date that they produce a 
conformational change upon binding. 
Ginkgolides thus bind close to the covalently 
linked fluorophore.  The results of Fig. 5G-K 
demonstrate that ginkgolide C-induced inhibition 
is accompanied by both an increase in ∆F and a 
blue shift in the emission spectra maxima. 
Unexpectedly, ginkgolide C affects ∆F at higher 
concentrations than those affecting ∆I (Fig. 5I). 
This is difficult to reconcile with a model that 
assumes only one ginkgolide molecule binding 
per receptor. We propose that the ∆F changes are 
mediated by ginkgolide C binding to a discrete, 
lower affinity site distinct from the well 
characterized pore blocker site at the 6’ level. In 
support of this, a molecular docking study 
identified a putative ginkgolide binding site near 
the M2-M3 loop (31). An alternate explanation is 
that the relatively large size of ginkgolides may 
force the pore to become stabilized in the 
activated state. However, the observed 
discrepancy between the ∆F and ∆I ginkgolide 
dose-responses is not readily explainable by this 
model. 
 
Comparison with previous VCF studies 
 Chang and Weiss (17) employed VCF to 
investigate molecular rearrangements at three 
positions in and around the recombinant ρ1 
GABAAR ligand binding pocket. They found that 
two GABAergic agonists produced a similar 
pattern of ∆F responses at the three labelled 
positions. Competitive antagonists prevented 
these ∆F changes but also produced distinct ∆F 
responses in the absence of agonist. Perhaps most 
interestingly, picrotoxin produced a large ∆F at 
one of the labelled positions, providing strong 
evidence that by binding in the pore it produces 
global conformational change (17). A more recent 
study on α1β2 and α1β2γ2 GABAARs showed 
that the ∆F magnitude monitored at two binding 
domain residues exhibited subunit-dependence 
(18). The results from these two studies provide 
strong evidence for ligand- and subunit-specific 
conformational changes in the ligand binding 
domain. However, they provide no information 
about whether these differential movements 
translate into different movements at the pore.  
    Finally, Dahan et al (15) investigated 
acetylcholine- and epibatidine- mediated ∆F and 
∆I changes at muscle (αβγδ) nAChRs via a 
rhodamine label attached to the β subunit 19’ 
position. They concluded that ∆F reported a 
conformational change at the αδ subunit 
interface.  The ∆F signal was also modulated by 
the receptor desensitization status. Together with 
the present study, these results indicate that the 
M2 conformation reflects a wide variety of 
influences, including the identity of the bound 
agonist, the molecular identity of the labelled 
subunit and the desensitization status of the 
receptor. 
 
Conclusion 
VCF recordings reveal that the GlyR 
agonists, glycine, taurine and ivermectin,  
produce different ∆F changes at fluorescently-
labeled 19’ and 22’ residues. The inhibitors, 
strychnine and picrotoxin, produced ∆F and ∆I 
changes as expected for a competitive antagonist 
and a channel blocker, respectively. On the other 
hand, the putative channel blocker, ginkgolide C, 
produced an increase in ∆F that may have 
signalled a direct interaction between MTSR and 
a low affinity ginkgolide site. Taken together, our 
results suggest that the GlyR M2 domain 
responds with distinct conformational changes to 
the binding of different agonists. 
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FIGURE LEGENDS 
 
Fig. 1. Effects of MTSR-labeling on α1WT and α1R19’C GlyRs. (A) Glycine-evoked currents 
recorded from oocytes injected with α1WT (upper panel) and α1R19’C (lower panel) after labeling 
with MTSR. (B) Glycine-evoked currents recorded from oocytes injected with α1WT (upper panel) or 
α1R19’C (lower panel) before (left panel) and after (right panel) labeling with MTSR (C) Glycine 
dose-response relations for α1WT and α1R19’C before and after labeling with MTSR. Black horizontal 
bars indicate duration of glycine application. All concentrations in mM. (D) Ribbon model of three 
pore-facing nAChR M2 helices and their M2-M3 linkers in black and grey (based on PDB code 2BG9). 
A space filling model of the 9’ leucine is shown in dark blue. A space filling model of MTSR molecule 
is tethered to the 19’ position (approximate orientation based on Lester, HA & Dibas MI, manuscript in 
preparation). Colour code: white: hydrogen; light blue: carbon; red: oxygen; dark blue: nitrogen and 
yellow: sulphur. 
 
Fig. 2. Close coupling of current and fluorescence changes and spectral analysis of MTSR-labeled 
α1R19’C oocytes. (A) Glycine-evoked current (upper panel) and fluorescence (lower panel) recordings 
from MTSR-labeled α1R19’C oocytes. (B) Glycine dose-response relation for current and fluorescence 
in MTSR-labeled α1R19’C oocytes. (C) Spectral emission from MTSR-labeled α1R19’C oocytes 
before, after and during the application of 1 and 30 mM glycine (average of 5 cells each). (D) 
Difference emission spectra from MTSR-labeled α1WT and α1R19’C oocytes recorded during 
application of glycine. Spectra recorded in the absence of glycine were subtracted from spectra recorded 
in the presence of glycine (average of 5 cells). Red and blue and traces were recorded in the presence of 
20 mM and 1 mM glycine concentrations, respectively. The black trace shows the difference emission 
spectrum obtained from a WT-injected oocyte after application of a saturating glycine concentration. 
Red and blue traces are shown normalized in the inset, along with the spectrum recorded in the absence 
of glycine (gray trace, normalized to the trace obtained with 1 mM glycine). 
 
 
Fig. 3. Effects of ivermectin, taurine and β-alanine on current and fluorescence from MTSR-labeled 
α1R19’C oocytes. (A) Current (upper panel) and fluorescence (lower panel) traces of MTSR-labeled 
α1R19’C oocyte during glycine (gly) and ivermectin (ivm) application. The fluorescence recording was 
interrupted to minimise photobleaching (B) Current (upper panel) and fluorescence (lower panel) traces 
of MTSR-labeled α1R19’C oocyte during glycine, ivermectin and simultaneous ivermectin and 
strychnine (str) application. (C, D) Current (upper panel) and fluorescence (lower panel) traces of 
MTSR-labeled α1R19’C oocytes during consecutive saturating glycine (gly) and taurine (tau) (A) or 
glycine and β-alanine (β-ala) (D) applications. Horizontal bars indicate duration of applications. (E) 
Current and fluorescence dose-response relations for glycine, taurine and β-alanine in MTSR-labeled 
α1R19’C oocytes. (F) Difference emission spectra from MTSR-labeled α1R19’C oocytes recorded 
during application of saturating [glycine] and [taurine]. Red and black traces are shown normalized in 
the inset, along with the spectrum recorded in the absence of glycine (grey trace, normalized to the trace 
obtained with 1 mM glycine).  (G) Difference emission spectra from MTSR-labeled α1R19’C oocytes 
recorded during application of saturating [glycine] and [β-alanine]. Red and black traces are shown 
normalized in the inset, along with the spectrum recorded in the absence of glycine (grey trace, 
normalized to the trace obtained with 1 mM glycine). Difference emission spectra were calculated as 
described in Fig. 2 (D). 
 
Fig. 4. The TMRM-labeled α1L22’C mutant GlyR differentiates between activation by glycine and 
taurine or β-alanine. (A) Examples of simultaneously recorded glycine-evoked current (upper panel) 
and fluorescence changes (lower panel) from MTSR-labeled α1L22’C GlyRs (left), from TMRM-
labeled α1L22’C GlyRs (center) and from MTSR-labeled α1R19’C GlyRs (right). Horizontal bars 
indicate duration of applications. Different fluorophores give different responses when attached to the 
same residue. (B) Glycine dose-response relations for currents in unlabeled and TMRM-labeled 
α1L22’C-expressing oocytes. TMRM labelling causes a significant leftward shift in glycine sensitivity. 
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(C) and (D) simultaneously recorded current (upper panel) and fluorescence (lower panel) recordings 
from TMRM-labeled α1L22’C oocytes following the application of 10 mM taurine and 3 mM glycine 
(C) or 10 mM β-alanine and 3 mM glycine (D). Dashed lines indicate periods of interrupted 
illumination to prevent photobleaching between applications. 
 
Fig. 5. Effects of GlyR inhibitors on current and fluorescence recordings from MTSR-labeled α1R19’C 
oocytes. (A) Current (upper panel) and fluorescence (lower panel) traces of MTSR-labeled α1R19’C 
oocyte during consecutive, saturating [strychnine] (str) and [glycine] (gly) applications as indicated by 
horizontal bars. (B) Current (upper panel) and fluorescence (lower panel) traces of MTSR-labeled 
α1R19’C oocyte during co-application of EC50 [glycine] with saturating [strychnine] (C) Current and 
fluorescence dose-response relations for the inhibition by strychnine when co-applied with 1 mM 
glycine. (D) Current (upper panel) and fluorescence (lower panel) traces of MTSR-labeled α1R19’C 
oocyte during consecutive, saturating [picrotoxin] (PTX) and [glycine] (gly) applications as indicated 
by horizontal bars. (E) Current (upper panel) and fluorescence (lower panel) traces of MTSR-labeled 
α1R19’C oocyte during co-application of EC50 [glycine] with saturating [picrotoxin] (F) Current and 
fluorescence dose-response relations for the inhibition by picrotoxin when co-applied with 1 mM 
glycine. (G) Current (upper panel) and fluorescence (lower panel) traces of MTSR-labeled α1R19’C 
oocyte during consecutive, saturating [ginkgolide C] (GC) and [glycine] (gly) applications as indicated 
by horizontal bars. (H) Current (upper panel) and fluorescence (lower panel) traces of MTSR-labeled 
α1R19’C oocyte during co-application of EC50 [glycine] with saturating [ginkgolide C] (I) Current and 
fluorescence dose-response relations for the inhibition by ginkgolide C when co-applied with 1 mM 
glycine. Horizontal scale bars: 20 seconds, vertical scale bars (upper panels): 2 µA, vertical scale bars 
(lower panels): 5 % ∆F. (J) Spectral emission from MTSR-labeled α1R19’C oocytes before, after, 
during the application of 1 mM glycine and 1 mM glycine + 100 µM ginkgolide C (average of 5 cells 
each). (K) Difference emission spectra from MTSR-labeled α1R19’C oocytes recorded during 
application of glycine and glycine + ginkgolide C, respectively. Both the grey trace (spectral emission 
before application of agonist) and the blue trace are normalized to the 1 mM glycine emission peak. 
Difference emission spectra were calculated as described in Fig. 2D. 
 
Fig. 6. Propofol effects on glycine-, taurine- and β-alanine-evoked currents in MTSR-labeled α1R19’C 
oocytes. (A) Glycine-evoked current (upper panel) and fluorescence (lower panel) recordings from 
MTSR-labeled α1R19’C oocytes after a 2 min. pre-incubation with 500 µM propofol (+Pro). (B) 
Glycine dose-response relation for current and fluorescence in MTSR-labeled α1R19’C oocytes with 
and without a 2 min. pre-incubation with 500 µM propofol. (C, D) Current (upper panel) and 
fluorescence (lower panel) recordings from MTSR-labeled α1R19’C oocytes during the application of 
30 mM glycine (black arrows), 50 mM taurine (blue arrows) and 50 mM β-alanine (red arrows). In (D) 
black horizontal bars indicate application of 500 µM propofol. (E) Taurine-evoked dose-response 
relation for current and fluorescence in MTSR-labeled α1R19’C oocytes with and without a 2 min. pre-
incubation with 500 µM propofol (+Pro). (F) β-Alanine-evoked dose-response relation for current and 
fluorescence in MTSR-labeled α1R19’C oocytes with and without a 2 min. pre-incubation with 500 µM 
propofol (+Pro). Dashed lines indicate interrupted illumination to prevent photobleaching between 
applications. (G, H) Difference emission spectra from MTSR-labeled α1R19’C oocytes recorded during 
application of saturating [taurine] (G) and [β-alanine] (H) before and after a 2 min. pre-incubation with 
500 µM propofol (+Pro), respectively. Emission peaks after propofol treatment were normalized to 
those recorded before propofol treatment. Difference emission spectra were calculated as described in 
Fig. 2D. 
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Table 1. Summary of results for glycine-evoked current and fluorescence recordings. Displayed are 
values for half-maximal activation (EC50), Hill coefficient (nH), number of experiments (n) and maximal 
current and fluorescence responses (Imax and ∆Fmax, respectively). All results for fluorescence are shown 
in red. 
 
Construct EC50 (µM) nH n Imax (µA) ∆Fmax (%) n 
αWT unlabeled  21.5 ± 0.1 2.9 ± 0.1 5 10.0 ± 0.6 n/a 9 
αWT labeled  19.1 ± 0.1 3.0 ± 0.1 6 8.7 ± 0.6 n/a 6 
αS21'C unlabeled 21.1 ± 0.1 1.9 ± 0.1 5 6.8 ± 0.3 n/a 5 
αS21'C labeled 24.3 ± 0.6 1.9 ± 0.1 3 6.2 ± 0.4 n/a 3 
αS22'C unlabeled 781.0 ± 7.2 1.2 ± 0.1 7 7.3 ± 0.8 n/a 7 
αS22'C labeled 215.7 ± 0.2 1.9 ± 0.1 6 7.7 ± 0.4 n/a 6 
αR19'C unlabeled 4450 ± 190 1.7 ± 0.1 7 9.3 ± 1.6 n/a 5 
αR19'C labeled  994 ± 14 1.7 ± 0.1 7 8.3 ± 0.6 n/a 19 
αR19'C ∆F  1074 ± 46 1.5 ± 0.1 7 n/a 21.4 ± 1.9 19 
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Table 2. Summary of results for glycine, taurine and β-alanine-evoked current and fluorescence 
recordings from MTSR-labeled α1R19’C oocytes. Results are shown for recordings before and after a 2 
min preincubation with 500 µM propofol (+PRO). Displayed are values for half-maximal activation 
(EC50), number of experiments (n) and maximal current and fluorescence responses (Imax and ∆Fmax, 
respectively). All results for fluorescence are shown in red. 
 
 
Agonist Construct EC50 ∆I (µM) EC50 ∆F (µM) n Imax (µA) ∆Fmax (%) n 
αR19'C 994 ± 14 1070 ± 46 7 8.3 ± 0.6 21.4 ± 1.9 19 
G
ly
ci
ne
 
αR19'C +PRO 419 ± 34 718 ± 108 6 10.5 ± 1.2 22.9 ± 2.7 8 
αR19'C 2610 ± 927 2030 ± 344 6 0.19 ± 0.03 13.2 ± 1.7 7 
β-
A
la
ni
ne
 
αR19'C +PRO 219 ± 4 381 ± 26 6 7.1 ± 0.4 17.1 ± 1.1 14 
αR19'C n/a 2350 ± 443 8 0.04 ± 0.01 7.6 ± 0.7 8 
T
au
ri
ne
 
αR19'C +PRO 749 ± 53 479 ± 49 5 3.3 ± 0.6 10.1 ± 0.6 13 
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